The prevalence of heart failure (HF) and chronic kidney disease (CKD) tends to increase in the general population as a consequence of the increasing age and improvement of the management and the outcome of acute cardiac and renal syndromes. Both conditions co-exist very often in one and the same patient which is probably due to “sharing” common risk factors like arterial hypertension, diabetes mellitus and atherosclerotic disease. It is considered that cardiac dysfunction may lead to renal failure and vice versa. The prevalence of CKD among patients with HF is around 30-40%. In recent years, we speak about cardiorenal syndrome (CRS) which is a pathophysiological condition of the heart and kidneys where the acute or chronic dysfunction of one of these organs leads to acute or chronic dysfunction of the other. For a more precise chronological and pathophysiological definition CRS is classified in 5 types. New biomarkers for renal impairment such as NGAL, KIM-1, NAG, Cystatin С are already in clinical practice. More vigilance and more frequent laboratory monitoring of serum creatinine and electrolytes is required in patients with HF and CKD who are treated with ACE inhibitors/angiotensin-receptor blocking agents and aldosterone antagonists.
Ангелов А, Йотов Й. Клинична характеристика и медикаментозно лечение при болни хоспитализирани с остра сърдечна недостатъчност. Разлики между двата пола. Българска кардиология 2013; 19: 46-50.
Витлянова, К., Т. Донова. Проспективно проучване при пациенти с хронична сърдечна недостатъчност. Клинична, инструментална и лабораторна характеристика на пациентите с хронична сърдечна недостатъчност. Българска кардиология 2011; 17: 40-46.
Георгиев Б. Кардиоренален синдром – определение, класификация, клинично значение и терапевтично поведение. Наука Кардиология 2013; 14: 261-277.
Димова М, стоянова Л, Маринова Е. Анемия, сърдечна недостатъчност и приложение на еритропоетин стимулиращи агенти, сп. Сърце-бял дроб, 23, 2017, стр. 9-18
Мирчева Л, Кишева А, Ангелов А, Кунчев О, Йотов Й. Особености на протичането на сърдечната недостатъчност при възрастни пациенти в болнични условия. Списание „Известия на Съюза на учените” – Варна 2012; 17: 25-28.
Каназирев Б, Георгиева Ж, Гинкова Я, Димова М, Небиволол – бета-блокер със специални ефекти, сп. „Наука Кардиология, кн. 6/2011, стр. 347-351
Стоянова Л, Стайкова В, Калева В, Димова М, Маринова Е, Нови уринни биомаркери за установяване на ранно бъбречно увреждане при болни с бета-таласемия майор. Сп. Нефрология, диализа и трансплантация, 2018, стр. 22-28
Стоянова Л, Стайкова С, Димова М, Маринова Е, NGAL (неутрофилен гелатиназа-асоцииран липокалин) – биомаркер за ранно бъбречно увреждане и прогресия на ХБЗ, сп. „Наука Кардиология“ 3/2018, стр. 103-106
Adams KF Jr, Fonarow GC, Emerman CL et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2005; 149: 209-216.
Ambrosy AP, Fonarow GC, Butler J et al. The global health and economic burden of hospitalizations for heart failure. Lessons learned from hospitalized heart failure registries. J Am Coll Cardiol 2014; 63; 1123-1133.
Berl T, Henrich W. Kidney-heart interactions: epidemiology, pathogenesis and treatment. Clin J Am Soc Nephrol 2006; 1: 8-18.
Bhatia RS, Tu JV, Lee DS et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 2006; 355: 260-269.
Bibbins-Domingo K, Lin F, Vittinghoff E e et al. Renal insufficiency as an independent predictor of mortality among women with heart failure. J Am Coll Cardiol 2004; 44: 1593-1600.
Blair JEA, Pang PS, Schrier RW et al. Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial. Eur Heart J 2011; 32: 2563-2572.
Bonventre JV, Yang L. Kidney injury molecule-1. Curr Opin Crit Care 2010; 16: 556-561.
Braunstein JB, Anderson GF, Gerstenblith G et al. Noncardiac comorbidity increases preventable hospitalizations and mortality among Medicare beneficiares with chronic heart failure. J Am Coll Cardiol 2003; 42; 1226-1233.
Butler J, Chirovsky D, Phatak H et al. Renal function, health outcomes, and resource utilization in acute heart failure. A systematic review. Circ Heart Fail 2010; 3: 726-745.
Butler J, Forman DE, Abraham WT et al. Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am Heart J 2004; 147: 331-338.
Colombo PC, Ganda A, Lin J et al. Inflammatory activation: cardiac, renal, and cardio-renal interactions in patients with the cardiorenal syndrome. Heart Fail Rev 2012; 17: 177-190.
Cowie MR, Komajda M, Murray-Thomas T et al. Prevalence and impact of worsening renal function in patients hospitalized with decompensated heart failure: results of the prospective outcomes study in heart failure (POSH). Eur Heart J 2006; 27: 1216-1222.
Damman K, Jaarsma T, Voors AA et al. Both in- and out-hospital worsening of renal function predict outcome in patients with heart failure: results from the Coordinating Study Evaluating Outcome of Advising and Counseling in Heart Failure (COACH). Eur J Heart Fail 2009; 11: 847-854.
Damman K, Masson S, Hillege HL et al. Clinical outcome of renal tubular damage in chronic heart failure. Eur Heart J 2011; 32: 2705-2712.
Damman K, Navis G, Smilde TD et al. Decreased cardiac output, venous congestion and the association with renal impairment in patients with cardiac dysfunction. Eur J Heart Fail 2007; 9: 872-878.
Damman K, Ng Kam Chuen MJ, MacFadyen RJ et al. Volume status and diuretic therapy in systolic heart failure and the detection of early abnormalities in renal and tubular function. J Am Coll Cardiol 2011; 57: 2233-2241.
Damman K, van Veldhuisen DJ, Navis G et al. Urinary neutrophil gelatinase associated lipocalin (NGAL), a marker of tubular damage, is increased in patients with chronic heart failure. Eur J Heart Fail 2008; 10: 997-1000.
Damman K, van Veldhuisen DJ, Navis G et al. Tubular damage in chronic systolic heart failure is associated with reduced survival independent of glomerular filtration rate. Heart 2010; 96: 1297-1302.
Damman K, Voors AA, Navis SG et al. Current and novel renal biomarkers in heart failure. Heart Fail Rev 2012; 17: 214-250.
Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis 2002; 40: 221-226.
Dickstein K, Cohen-Solal A, Filippatos G et al. Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Eur Heart J 2008; 29: 2388-2442.
Erdmann E, Lechat P, Verkenne P et al. Results from post-hoc analyses of the CIBIS II trial: Effect of bisoprolol on high-risk patient groups with chronic heart failure. Eur J Heart Fail 2001; 3: 469-479.
Ezekowitz J, McAllister FA, Humphries KH et al. The association among renal insufficiency, pharmacotherapy, and outcomes in 6427 patients with heart failure and coronary artery disease. J Am Coll Cardiol 2004; 44: 1587-1592.
Felker GM, Lee KL, Bull DA et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med 2011; 364: 797-805.
Go As, Yang J, Ackerson Lm et al. Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure. The Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study. Circulation 2006; 113: 27134-2723.
Godfarb M, Abassi Z, Rosen S et al. Compensated heart failure predisposes to outer medullary tubular injury: studies in rats. Kidney Int 2001; 60: 607-613.
Goldsmith SR, Sobotka PA, Bart BA. The sympathorenal axis in hypertension and heart failure. J Card Fail 2010; 16: 369-373.
Haase M, Devarajan P, Haase-Fielitz A et al. The outcome of neutrophil gelatinase-associated lipocalin-positive subclinical acute kidney injury: a multicenter pooled analysis of prospective studies. J Am Coll Cardiol 2011; 57: 1752-1761.
Hasselblad V, Gattis Stough W, Shah MR et al. Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial. Eur J Heart Fail 2007; 9: 1064-1069.
Hebert K, Dias A, Delgado MC et al. Epidemiology and survival of the five stages of chronic kidney disease in a systolic heart failure population. Eur J Heart Fail 2010; 12: 861-865.
Herget-Rosenthal S, Maggraf G, Husing J et al. Early detection of acute renal failure by serum cystatin C. Kidney Int 2004; 66: 1115-1122.
Hernandez AF, Greiner MA, Fonarow GC et al. Relationship between early physician follow-up and 30-day readmission among medicare beneficiaries hospitalized for heart failure. JAMA 2010; 303: 1716-1722.
Hillege HL, Nitsch D, Pfeffer MA et al. Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Investigators. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 2006; 113: 671-678.
Jackson CE, MacDonald MR, Petrie MC et al. Aliskiren Observation of Heart Failure Treatment (ALOFT) investigators. Associations of albuminuria in patients with chronic heart failure: findings in the Aliskiren Observation of Heart Failure Treatment study. Eur J Heart Fail 2011; 13: 746-754.
Jackson CE, Solomon SD, Gerstein HC et al. CHARM Investigators and Committees. Albuminuria in chronic heart failure : prevalence and prognostic importance. Lancet 2009; 374: 543-550.
Japp A, Newby D. Comorbidities associated with chronic heart failure. In Chronic heart failure. Edited by Kearney M., Oxford University Press, 2008.
Jessup M, Abraham WT, Casey DE et al. 2009 focused update: ACCF/AHA Guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119: 1977-2016.
Juurlink DN, Mamdani MM, Lee DS et al. Rates of hyperkaliemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004; 351: 543-545.
KDOQI. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 2007; 49: S12-S154.
Klein L, Massie BM, Leimberger JD et al. Admission or changes in renal function during hospitalization for worsening heart failure predict postdischarge survival. Results from the outcomes of a prospective trial of intravenous milrinone for exacerbations of chronic heart failure (OPTIMIZE-CHF). Circ Heart Fail 2008; 1: 25-33.
Kliger AS, Foley RN, Goldfarb DS, Goldstein SL, Johansen K, Singh A,Szczech L. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for anemia in CKD. Am J Kidney Dis. 2013;62:849–859
Lang CC, Manchini DM. Non-cardiac comorbidities in chronic heart failure. Heart 2007; 93: 665-671.
Lassus JPE, Nieminen MS, Peuhkurinen K et al. Markers of renal function and acute kidney injury in acute heart failure: definitions and impact on outcomes of the cardiorenal syndrome. Eur Heart J 2010; 31: 2791-2798.
Levy WC, Mozaffarian D, Linker DT et al. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation 2006; 113: 1424-1433.
Masoudi FA, Rathore SS, Wang Y et al. National patterns of use and effectiveness of angiotensin-converting enzyme inhibitors in older patients with heart failure and left ventricular systolic dysfunction. Circulation 2004; 110: 724-731.
Maxwell AP, Ong HY, Nicholls DP. Influence of progressive renal dysfunction in chronic heart failure. Eur J Heart Fail 2002; 4: 125-130.
McAlister FA, Ezekowitz J, Tonelli M et al. Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. Circulation 2004; 109: 1004-1009.
McMurray JJV, Adamapoulus S, Anker SD et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur Heart J 2012; 33: 1787-1847.
Metra M, Cottеr G, Gheorghiade M et al. The role of the kidney in heart failure. Eur Heart J 2012: 33: 2135-2143.
Metra M, Davison B, Bettari L et al. Is worsening renal function on ominous prognostic sign in patients with acute heart failure? The role of congestion and its interaction with renal function. Circ Heart Fail 2012; 5: 54-62.
Metra M, Nodari S, Parrinello G et al. Worsening renal function in patients hospitalised for acute heart failure: Clinical implications and prognostic significance. Eur J Heart Fail 2008; 10: 188-195.
Meyer TW, Hostetter TH. Uremia. N Engl J Med 2007; 357: 1316-1325.
O’Connor CM, Starling RC, Hernandez AF et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 2011; 365: 32-43.
Pfister R, Diedrichs H, Schiedermair A et al. Prognostic impact of NT-proBNP and renal function in comparison top contemporary multi-marker risk scores in heart failure patients. Eur J Heart Fail 2008; 10: 315-320.
Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Eur Heart J 2016; 37 (27): 2129-2200
Ronco C, Cicoira М, McCullough PA. Cardiorenal syndrome type 1. J Am Coll Cardiol 2012; 60: 1031-1042.
Ronco C, Haapio M, House AA. Cardiorenal syndrome. J Am Coll Cardiol 2008; 52: 1527-1539.
Rossignol P, Cleland JG, Bhandari S et al. Determinants and consequences of renal function variations with aldosterone blocker therapy in heart failure patients after myocardial infarction: insights from the eplerenone post-acute myocardial infarction heart failure efficacy and survival study. Circulation 2012; 125: 271-279.
Ruggenenti P, Remuzzi P. Worsening kidney function in decompensated heartn failure: treat the heart, don’t mind the kidney. Eur Heart J 2011; 32: 2476-2478.
Schrier RW. Blood urea nitrogen and serum creatinine: not married in heart failure. Circ Heart Fail 2008; 1: 2-5.
Schrier RW, Shchekochikhin D. Assessment of renal function in heart failure. J Am Coll Cardiol 2012: 59: 1716-1718.
Scrutinio D, Passantino A, Santoro D et al. The cardiorenal anaemia syndrome in systolic heart failure: prevalence, clinical correlates, and long-term survival. Eur J Heart Fail 2011; 13: 61-67.
Silverberg DS, Wexler D, Iaina A et al. Anemia, chronic renal disease and congestive heart failure – the cardio renal anemia syndrome: the need for cooperation between cardiologists and nephrologists. Int Urol Nephrol 2006; 38: 295-310.
Smith GL, Lichtman JH, Bracken MB et al. Renal impairment and outcomes in heart failure. Systematic review and meta-analysis. J Am Coll Cardiol 2006; 47: 1987-1996.
Smith GL, Shlipak MG, Havranek EP et al. Race and renal impairment in heart failure: mortality in blacks versus whites. Circulation 2005; 111: 1270-1277.
Tang YD, Katz SD. Anemia in chronic heart failure. Prevalence, etiology, clinical correlates, and treatment options. Circulation 2006; 113: 2454-2461.
Testani JM, Chen J, McCauley et al. Potential effects of aggressive decongestion during the treatment of decompensated heart failure on renal function and survival. Circulation 2010; 122: 265-272.
Uchino S, Bellomo R, Goldsmith D et al. An assessment of the RIFLE criteria for acute renal failure in hospital patients. Crit Care Med 2006; 34: 1913-1917.
van der Meer P, van Veldhuisen DJ. Anaemia and renal dysfunction in chronic heart failure. Heart 2009; 95: 1808-1812.
Vaz Perez A, Otawa K, Zimmermann AV et al. The impact of impaired renal function on mortality in patients with acutely decompensated chronic failure. Eur J Heart Fail 2010; 12: 122-128.
